Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting HDAC11 to combat hepatocellular carcinoma and regulate alternative RNA splicing

Award Number: F31CA284578
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2025

Group Awards By:

View Award Description

Targeting HDAC11 to combat hepatocellular carcinoma and regulate alternative RNA splicing - PROJECT SUMMARY Liver cancer incidence and mortality continue to rise, and new therapeutic targets are needed. This fellowship application will explore how the enzyme histone deacetylase eleven (HDAC11) drives liver cancer, and tests HDAC11 as a potential new target for therapy. HDAC11 acts primarily as a lysine fatty acid (KFA) hydrolase, an enzyme that removes fatty acids from proteins (de-KFA). HDAC11 is expressed at low levels in most healthy tissues, but is increased in liver cancer, and high levels are significantly correlated with poor patient outcomes. Proteomic studies have implicated HDAC11 in alternative mRNA splicing, which is prevalent in most cancers. The overall goal of this application is to understand the role of HDAC11 in liver cancer and assess the potential of new, highly specific HDAC11 small molecule inhibitors. In two aims, this application will test the hypothesis that HDAC11 promotes hepatocellular carcinoma through de-KFA of the splicing factor SF3B2, and that inhibiting HDAC11 will block hepatocellular carcinoma progression. In Aim 1, SF3B2 will be authenticated as an HDAC11 substrate in established hepatocellular carcinoma cell lines using a click chemistry-based approach. Preliminary data confirms the feasibility of this technique and establishes that SF3B2 can be lysine fatty acylated. Proposed studies will test if HDAC11-mediated de-KFA of SF3B2 changes its nuclear localization, thereby changing its ability to regulate RNA splicing in the nucleus and resulting in alternative mRNA expression. To detail the alternative splicing outcomes driven by HDAC11, mRNA isoform specific long read sequencing will be conducted. The abundance of isoform specific alternative mRNAs in HDAC11 wild type versus knockout and inhibitor-treated liver cancer will be quantified. In Aim 2, HDAC11 specific small molecule inhibitors will be tested to establish HDAC11 inhibition as a potential cancer treatment approach. Preliminary data show that HDAC11 inhibition specifically decreases colony formation and increases drug sensitivity, leading to the inference that HDAC11 may promote cancer cell stemness characteristics such as self-renewal and drug resistance. Oncogenesis in vivo will be tested following wildtype, knockout, and inhibitor treatments with disease progression monitored by luminescence imaging. This study will provide new knowledge on the molecular functions of HDAC11 in alternative mRNA splicing and liver cancer progression, and evaluate clinically-relevant small molecule inhibitors for potential liver cancer treatment. Completion of the proposed project will develop necessary research and professional skills that are essential for a career as a cancer investigator.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = -$6,060 )
2027	2025	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Research Manpower	000	2	10/27/2026	NON-COMPETING CONTINUATION	-$6,060
														Subtotal = -$6,060

Issue Date FY: 2026 ( Subtotal = -$9,596 )
2026	2025	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Research Manpower	000	2	1/7/2026	NON-COMPETING CONTINUATION	-$9,596
														Subtotal = -$9,596

Issue Date FY: 2025 ( Subtotal = $39,388 )
2025	2025	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Research Manpower	000	2	8/1/2025	NON-COMPETING CONTINUATION	$39,388
														Subtotal = $39,388

Issue Date FY: 2024 ( Subtotal = $43,504 )
2024	2024	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Research Manpower	000	1	3/12/2024	NEW	$42,224
2024	2024	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Research Manpower	002	1	5/7/2024	NEW	$1,280
2024	2024	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Cancer Research Manpower	001	1	3/12/2024	NEW	$0
														Subtotal = $43,504

Grand Total All Awards = $67,236

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting HDAC11 to combat hepatocellular carcinoma and regulate alternative RNA splicing

Award Number: F31CA284578

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer